Literature DB >> 17509661

Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis.

Yong Hannah Wen1, Hartmut Koeppen, Roberto Garcia, Luis Chiriboga, Branden D Tarlow, Brock A Peters, Charles Eigenbrot, Herman Yee, German Steiner, M Alba Greco.   

Abstract

Activation of intracellular mitogenic signal transduction pathways driven by the ErbB family of receptor tyrosine kinases has been implicated in the development and/or progression of a variety of cancers. Studies on ErbB receptors in osteosarcoma have focused on HER-2 and have produced conflicting results with few studies evaluating the expression of the epidermal growth factor receptor (EGFR). In this study, we determined the level of expression of EGFR and the mutational status of the EGFR receptor in a subset of osteosarcoma tumor samples as well as in a series of established bone tumor-derived cell lines. EGFR protein expression was detected in the form of strong membranous staining by immunohistochemistry in 21 (57%) of 37 cases analyzed. Six of 12 (50%) osteosarcoma cell lines revealed moderate to high expression levels of EGFR. Two somatic alterations (E829E and R831C) were identified in the cytoplasmic domain of the EGFR gene in 1 of 10 tumor samples. The significance of these findings for the pathobiology of osteosarcomas will be investigated further.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509661     DOI: 10.1016/j.humpath.2007.01.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  27 in total

1.  High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.

Authors:  Edwin Choy; Francis Hornicek; Laura MacConaill; David Harmon; Zeeshan Tariq; Levi Garraway; Zhenfeng Duan
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

2.  Detection limits of intraoperative near infrared imaging for tumor resection.

Authors:  Greg M Thurber; Jose-Luiz Figueiredo; Ralph Weissleder
Journal:  J Surg Oncol       Date:  2010-12-01       Impact factor: 3.454

Review 3.  Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.

Authors:  Patrick J Messerschmitt; Ashley N Rettew; Robert E Brookover; Ryan M Garcia; Patrick J Getty; Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2008-07-08       Impact factor: 4.176

4.  Met interacts with EGFR and Ron in canine osteosarcoma.

Authors:  J K McCleese; M D Bear; S K Kulp; C Mazcko; C Khanna; C A London
Journal:  Vet Comp Oncol       Date:  2011-12-08       Impact factor: 2.613

Review 5.  Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.

Authors:  Wei Wang; Hua-Fu Zhao; Teng-Fei Yao; Hao Gong
Journal:  Invest New Drugs       Date:  2018-10-24       Impact factor: 3.850

Review 6.  Strategies for the targeted delivery of therapeutics for osteosarcoma.

Authors:  Dennis P M Hughes
Journal:  Expert Opin Drug Deliv       Date:  2009-12       Impact factor: 6.648

7.  Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.

Authors:  Serena S Freeman; Steven W Allen; Ramapriya Ganti; Jianrong Wu; Jing Ma; Xiaoping Su; Geoff Neale; Jeffrey S Dome; Najat C Daw; Joseph D Khoury
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

8.  Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions.

Authors:  Mandy Geryk-Hall; Dennis P M Hughes
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

Review 9.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

10.  Afatinib is active in osteosarcoma in osteosarcoma cell lines.

Authors:  Marlid Cruz-Ramos; Yessica Zamudio-Cuevas; Daniel Medina-Luna; Karina Martínez-Flores; Gabriela Martínez-Nava; Javier Fernández-Torres; Alberto López-Reyes; Flavio Solca
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-24       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.